Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

This study is investigating whether patients with triple-negative breast cancer (TNBC) who still have detectable cancer DNA in the blood (called circulating tumor DNA or ctDNA) after initial chemotherapy should receive additional targeted 'boost' therapy to eliminate remaining cancer cells. **You may be eligible if...** - You have been diagnosed with stage II or III triple-negative breast cancer - Your cancer is triple-negative (low or no hormone receptors, HER2-negative) - You are receiving or planning to receive standard chemotherapy before surgery (neoadjuvant therapy) **You may NOT be eligible if...** - You have inflammatory breast cancer, occult (hidden) breast cancer, or metaplastic breast cancer - (No further specific exclusion criteria were listed) Talk to your doctor to see if this trial is right for you.